Business
Tenon(R) Medical Issues Shareholder Letter and Provides Preliminary Revenue for the Fourth Quarter and Full Year 2025
Fourth Quarter 2025 Revenue of $1.45 to $1.48 Million, representing growth of ~90% year over year. Full Year 2025 Revenue of $3.91 to $3.94 Million, representing growth of ~20% year over year. LOS GATOS, CA / ACCESS Newswire / January 28, 2026 / Tenon ...
About this update from Tenon Medical, Inc.
[{"type":"text","content":"Fourth Quarter 2025 Revenue of $1.45 to $1.48 Million, representing growth of ~90% year over year.","length":98,"tagName":"p"},{"type":"text","content":"Full Year 2025 Revenue of $3.91 to $3.94 Million, representing growth of ~20% year over year.","length":93,"tagName":"p"},{"type":"text","content":"LOS GATOS, CA / ACCESS Newswire / January 28, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today issued a letter to shareholders from Steve Foster, President and Chief Executive Officer.","length":308,"tagName":"p"},{"type":"text","content":"Dear Fellow Shareholders,","length":25,"tagName":"p"},{"type":"text","content":"2025 was marked by strong commercial execution as we advanced innovation and expanded our differentiated solutions in the marketplace. We delivered both sequential and year over year revenue growth and strengthened our liquidity position, placing Tenon on firmer financial footing heading into 2026. Our expanding product portfolio-driven by the acquisition of sacroiliac joint-specific assets from SiVantage and the recent FDA clearance and commercialization of the SImmetry®+ SI Joint Fusion System-positions us to scale revenue and address a broader range of sacro-pelvic fixation and fusion needs. Entering 2026, we have laid a strong foundation for sustained growth through portfolio diversification, commercial expansion, and improved operational alignment.","length":763,"tagName":"p"},{"type":"text","content":"Preliminary Fourth Quarter & Full Year 2025 Revenue","length":55,"tagName":"p"},{"type":"text","content":"Following record revenue growth in the third quarter, the Company is reporting preliminary, unaudited fourth quarter revenue of approximately $1.45 to $1.48 million for the period ended December 31, 2025, representing approximately 90% growth compared to the fourth quarter ended December 31, 2024. Preliminary unaudited full year 2025 revenue is expected to be approximately $3.91 to $3.94 million, representing approximately 20% year over year growth. Revenue acceleration in the second half of 2025 was driven by strong procedural volume momentum, which we expect to continue into 2026. This momentum was primarily fueled by adoption among new physician users of both the Catamaran® and SImmet...